Press Releases

MERS-CoV vaccine is safe and induces strong immunity in Army-led first-in-human trial

The Walter Reed Army Institute of Research conducted a Phase 1 first-in-human trial of a Middle East respiratory syndrome coronavirus vaccine candidate that was shown to be safe, well-tolerated, and induced a robust immune response comparable to response seen in survivors of natural MERS CoV infection. Initial findings were published today in The Lancet Infectious Diseases and have prompted further trials of the vaccine co-developed by GeneOne Life Science Inc. and Inovio Pharmaceuticals.